BiogenMEX:BIIB 59 FCF Margin % is 22.57% as of Mar. 2026, which is 15% below its 10-year median of 26.68. GuruFocus rates MEX:BIIB with a GF Score™ of 59/100 and a GF Value™ of MXN3,205.98 (Fairly Valued). The stock has 7 warning signs investors should review. Among 958 Drug Manufacturers companies, Biogen ranks better than 92.48% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biogen's Free Cash Flow for the
three
months ended in Mar. 2026 was MXN10,086 Mil. Biogen's Revenue for the
three
months ended in Mar. 2026 was MXN44,681 Mil. Therefore, Biogen's FCF Margin % for the quarter that ended in Mar. 2026 was 22.57%.
The historical rank and industry rank for Biogen's FCF Margin % or its related term are showing as below:
MEX:BIIB'
s FCF Margin % Range Over the Past 10 Years
Min: 11.22 Med: 26.68 Max: 44.58
Current: 23.2
During the past 13 years, the highest FCF Margin % of Biogen was 44.58%. The lowest was 11.22%. And the median was 26.68%.
MEX:BIIB's FCF Margin % is ranked better than 92.48% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs MEX:BIIB: 23.20
Biogen FCF Margin % Related Terms
Biogen FCF Margin % Historical Data
* Premium members only.
The historical data trend for Biogen's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BIIB vs OGN, AMRN, SCLX: FCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Biogen's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogen's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Biogen's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen (MEX:BIIB) has a FCF Margin % of 22.57% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biogen and its competitors. This is 15% below median its historical median of 26.68. Over the past decade, Biogen's FCF Margin % has ranged from 11.22 to 44.58. According to the industry distribution chart, Biogen ranks #72 out of 958 companies in the Drug Manufacturers industry, placing it in the top 7.5%.
Is Biogen's FCF Margin % too high?
Biogen's current FCF Margin % of 22.57% is 15% below median its 10-year median of 26.68. Over the past 10 years, this metric has ranged from a low of 11.22 to a high of 44.58. The Drug Manufacturers industry median FCF Margin % is 2.51. Biogen's value of 22.57% is 799.2% above this industry median. Based on the distribution chart, Biogen ranks #72 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biogen has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's FCF Margin % compare to OGN and AMRN?
According to the Drug Manufacturers industry distribution chart, Biogen ranks #72 out of 958 companies for FCF Margin %. This places Biogen in the top 8% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.51. Biogen's value of 22.57% is 799.2% above this benchmark. Historically, Biogen's own FCF Margin % has ranged from 11.22 to 44.58 over the past decade. While the company's 10-year median is 26.68 vs. the industry median of 2.51, Biogen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogen's current FCF Margin % of 22.57% is 799.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biogen and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogen's current FCF Margin % is 22.57%, which is 15% below median its own 10-year median of 26.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (MEX:BIIB) is currently considered Fairly Valued. The stock's GF Value™ is MXN3,205.98, compared to a current price of MXN3,335.50 — trading 4% above its estimated fair value. The current FCF Margin % is 22.57%, which is 15% below median its 10-year median of 26.68 and 799.2% above the Drug Manufacturers industry median of 2.51. Biogen's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Biogen (MEX:BIIB), the current FCF Margin % is 22.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogen (MEX:BIIB) Overvalued in 2026?
Based on GuruFocus' analysis, Biogen stock appears to be overvalued.
The current stock price of MXN3,335.50 is trading 4% above its estimated GF Value™ of MXN3,205.98.
GuruFocus considers Biogen to be Fairly Valued.
Key valuation signals for MEX:BIIB:
FCF Margin %: 22.57% (15% below median its 10-year median of 26.68)
GF Value™: MXN3,205.98 vs. price of MXN3,335.50 (4% above fair value)
Industry Position: 799.2% above the Drug Manufacturers median (#72 of 958)
No single metric tells the full story. See the MEX:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
59GF Score
Get the complete analysis for MEX:BIIB
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BIIB has been successfully added to your 
